LUMABS BV

...from UN statement: "Building a Future for Women in Science 2025 marks the 10th anniversary of the International Day of Women and Girls in Science (IDWGS) and the 30th anniversary of the Beijing Declaration and Platform for Action, two significant milestones in the global effort to promote gender equality and women's empowerment. Gender equality in science is crucial for building a better future for all, yet women and girls continue to face systemic barriers and biases in pursuing scientific careers. Closing the gender gap in science requires breaking stereotypes, promoting role models to inspire girls, supporting women's advancement through targeted programs, and fostering inclusive environments through policies and actions that promote inclusion, diversity and equity." #WomenInScience

Welcoming a New Generation of Talent: Maxime van den Oetelaar is here! 💡 At LUMABS BV, we’re all about nurturing fresh talent and empowering the next generation of innovators. We're excited to welcome in 2025 Maxime van den Oetelaar who will bring new energy, creativity, and unique perspectives to our team. Our company culture thrives on collaboration, growth, and innovation. We can’t wait to see the contributions Maxime van den Oetelaar will make as she embarks on this journey with us.

https://lnkd.in/eCRJCbwK

🚀 Exciting News from Sabiad BV! We are thrilled to announce that Sabiad BV has been awarded a valorization grant by Samenwerkingsverband Noord-Nederland (SNN) for our groundbreaking project focused on improving the diagnosis and treatment of infections following Total Joint Replacements (TJRs).   Each year, millions of people undergo TJRs, with the number expected to double by 2043. However, these surgeries come with risks, including serious bacterial infections, particularly those caused by Staphylococcus aureus (SA). Timely and accurate diagnosis is crucial, yet current diagnostic methods often fall short.   Together with our partners, LUMABS BV and UMCG Innovation Center/ UMCG research, we aim to develop a highly sensitive, specific, and rapid point-of-care test to detect SA infections. This test will enable healthcare providers to swiftly differentiate between sterile inflammation and dangerous infections, ultimately saving lives and reducing unnecessary antibiotic use, a key factor in combating antibiotic resistance.   🌟 Project Highlights: Innovation: Utilization of monoclonal antibodies and bioluminescent sensor technology for a revolutionary diagnostic approach. Impact: Significant contributions to public health, healthcare efficiency, and the sustainability of medical treatments. Regional Growth: Strengthening the innovation ecosystem and economic development in Northern Netherlands.   We are proud to contribute to the advancement of healthcare and the strengthening of Northern Netherlands' position as a leader in infection treatment and diagnostics. Stay tuned for more updates as we progress with this exciting initiative!   #HealthcareInnovation #Diagnostics #ValorizationGrant #Sabiad #NorthernNetherlands #MedicalResearch Ton van den Hoven Saskia van den Dool Paul Jutte Antonio Ornelas PNO Consultants - Nederland

Bij De Plantijn werken we aan de toekomst van de gezondheidszorg. Het Health & Innovation District Amsterdam (Hid) in Amsterdam, een belangrijk onderdeel van onze wijk, heeft steun ontvangen van Kansen voor West om innovatie binnen het mkb te versnellen. Samen met partners Sanquin, LUMABS BV en SanaGen B.V., richt het Hid infra project zich op de ontwikkeling van nieuwe medicijnen en diagnostiek. Dit driejarige project speelt een cruciale rol in het versterken van de #infrastructuur voor #onderzoek en #ontwikkeling. Met een geavanceerde omgeving die gericht is op #innovatie, zal HID-INFRA bijdragen aan snellere doorbraken in medische #technologieën en #behandelingen. Dit is een belangrijke stap in het bevorderen van betere en efficiëntere zorgoplossingen. De Plantijn blijft zich inzetten als een plek waar zorg, wonen, werken en innovatie samenkomen, met dit project als een sleutelmoment in de verdere ontwikkeling van een duurzaam zorgdistrict.

...thank you Health & Innovation District Amsterdam (Hid) for the invitation to present LUMABS BV innovative rapid diagnostic technology ideal for implementation in lower-income communities to the HEALTH CARE ADMINISTRATION, FLORIDA AGENCY FOR team and the City of Amsterdam as well as the conversation with our colleagues from Sanquin Research, Self-screen B.V. and 3D-PharmXchange towards future collaborations!

"We invest millions in technological dreams of the future like the hyperloop, but we take the ingenious success of the bicycle for granted." 🚲🏆 That's why Jan Ploeger spent his retirement time on a PhD thesis about the Dutch intellectual marriage of bicycle and train. A unique success that other countries envy in the battle against increasing car traffic. The 70-year-old Ploeger received his doctorate from the department of Industrial Engineering & Innovation Sciences at TU/e. Congratulations to him 🍾🥂!! How did that unique success came about and what we can learn from it? Find out here: https://lnkd.in/ejz4btf9

The Environmental Impact of Medical Waste Disposal What is Medical Waste? Any waste that is of a medical or laboratory origin can be classified as medical waste. This includes hospitals, laboratories, mortuaries, human as well as animal testing and research centres, blood banks, and nursing homes.  According to the World Health Organization (WHO), there are 8 types of medical waste:  Infectious waste, including discarded diagnostic materials, waste from treating infected patients and animals, and autopsies.  Pathological waste, including contaminated human and animal tissues and organs. Sharps waste, including syringes, needles, scalpels, and blades. Chemical waste, including solvents and reagents for laboratory use but also leakage of heavy metals through broken thermometers and batteries. Pharmaceutical waste, including unused or expired but contaminated drugs and vaccines. Cytotoxic waste, including substances with genotoxic properties such as cytotoxic drugs used in cancer treatment. Radioactive waste, including contaminated diagnostic and radiotherapeutic materials.  Non-hazardous or general waste, including other miscellaneous waste that is of a medical or laboratory origin but is not contaminated. LUMABS BV is the first Green Laboratory DIAGNOSTIC Technology for Hospitals, Laboratories, Animal testing and Research Centres! We bring a faster, less expensive, near-zero waste Diagnostic solution that DIRECTLY addresses the environmental impact of Diagnostic (biomedical) Waste! LUMABS BV INNOVATIVE Diagnostic ImmunoAssays reduce the cost of Healthcare: - use 90% less components than current immunoassays - easy to use, fast - less time - reduce the energy costs (less time to results, less equipment use, less resource/infrastructure use) - reduce the waste disposal costs (90% less waste volume to be collected, transported and treated at dedicated waste plant) - reduce the environmental impact of waste disposal (90% less waste generated, no hazardous components) All of this while at the same time LUMABS BV immunoassays provide: - faster diagnostic results (<30min) - better diagnostic results (higher sensitivity) - on-site/near-patient results #immunoassay #immunology #elisa #bioluminescence #diagnostics #healthcareinnovation #healthcaresustainability #sustainability #NLC #IL6 #TNFα #CRP #PCT #poct #sepsis #antimicrobialresistance #TDM #Hid #veterinarymedicine #veterinarydiagnostics #TUe #Sanquin

...have you checked our website for information on our patented #RAPPID and other homogeneous immunoassay bioluminescence sensor technologies ? ...at the same time discover why it is the FIRST sustainable, environmental friendly #GREEN #DIAGNOSTICTECHNOLOGY that is revolutionising #clinicaldiagnostics and brings a disruptive solution for the negative environmental footprint of current #clinicaldiagnostics  #waste. #immunoassay #immunology #elisa #bioluminescence #diagnostics #healthcareinnovation #healthcaresustainability #sustainability #NLC #IL6 #TNFα #CRP #PCT #poct #sepsis #antimicrobialresistance #TDM #Hid #veterinarymedicine #veterinarydiagnostics #TUe #Sanquin

...discover the full potential of LUMABS BV innovative, patented #bioluminescence diagnostic assays focusing on #Inflammation #Sepsis or for #veterinary diagnostics ...do you want to explore the full potential of your #biomarker with a detection technology that has a verifiable high diagnostic Sensitivity to deliver accurate results within a wide dynamic range? and do you also want to add the highest diagnostic Speed due to its simple three-step procedure that provides results within minutes? with a immunoassay CV value of <5% (Inter- and Intra-Assay Coefficients of Variability) ? then look now further than our #LumabsBRET and #RAPPID sensor technologies #immunoassay #immunology #elisa #bioluminescence #diagnostics #healthcareinnovation #healthcaresustainability #sustainability #nlc #IL6 #TNFα #CRP #PCT #poct #sepsis #antimicrobialresistance #TDM #Hid #veterinarymedicine